Related Experiment Video
Updated: Jun 18, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
Chronic beta-adrenergic activation-induced left ventricular systolic dysfunction is associated with systemic release
Santosh Kumar1, Sandeep Seth, Amardeep Jaiswal
1Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India.
Abstract:
The relationship between systemic cytokine release and chronic beta-adrenergic activation-induced left ventricular dysfunction (LVSD) has not been widely reported in the literature. In the present study,we examined changes in the serum levels of inflammatory cytokines (IL-1-beta, IL-6 and TNF-alpha) following chronic beta-adrenergic activation-induced LVSD. Male Wistar rats were administered isoproterenol (ISO, 5 mg/kg, sc, once daily) for 4 weeks (ISO 4) or 12 weeks (ISO 12). Echocardiography was done and serum levels of IL-1-beta, IL-6 and TNF-alpha were estimated at the end of each protocol. In the ISO 4 group, there was a significant increase in relative wall thickness (p < 0.01) and heart weight: body weight ratio (p < 0.001) without any significant changes in fractional shortening (FS) or serum cytokine levels. However, in the ISO 12 group, there was a 32% decrease in FS along with increased serum levels of IL-1-beta and TNF-alpha. The present findings indicate that LVSD induced by chronic beta-adrenergic activation in rats is accompanied by increased serum cytokine levels.
Related Concept Videos
Heart Failure II: Pathophysiology
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers